Close
CDMO Safety Testing 2026
Novotech

TrialScope Launches Second Global Clinical Trial Disclosure Maturity Assessment 

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been...

Cantex and Headlamp Target MS Depression Using Lumos AI

Cantex Pharmaceuticals and Headlamp Health have entered a collaboration...

VoxCell and adMare Partner on Antibody Therapy Research

VoxCell BioInnovation Inc. and adMare BioInnovations have entered a...
- Advertisement -

TrialScope, the global leader in clinical trial transparency and compliance solutions announced the release of its second Clinical Trial Disclosure Maturity Survey for clinical trial sponsors to perform self-assessments of their disclosure practices.

The measurement tool, launched in 2015, tracks clinical trial disclosure trends, clinical trial requirements and trial sponsors’ current practices from across the life sciences industry. The assessment is designed to allow sponsors to identify their organization’s capabilities, recognize best practices and benchmark their capabilities against their peers.  

Clinical trial sponsors seeking to participate in the 2017 Clinical Trial Maturity Assessment can access the tool here

Upon completion of the assessment, sponsors will receive an evaluation relative to their peers, with all competitor data remaining anonymous. In addition, all participants will receive a report based on responses, which can be used to document current disclosure maturity and assess opportunities for improvement. 

“The Clinical Trial Disclosure Maturity Assessment has provided valuable insight into current disclosing practices and emerging trends,” states TrialScope Chief Strategy Officer and Assessment Author Thomas Wicks, “Using this tool, we have been able to identify shifts in disclosure focus, scope and capabilities and reflect them back to participating clinical trial sponsors for benchmarking purposes. The results help sponsors gauge their own performance and take advantage of their strengths while developing plans to address any gaps in their practices.” 

Over 50 clinical trial sponsors participated in the first assessment in 2015 and the results were published in a white paper titled, “Clinical Trial Reporting Compliance: Self-Assessment Survey Results from Pharma, Biotech, and Academic Trial Sponsors”

About TrialScope
TrialScope simplifies the complexities of clinical trial transparency. TrialScope’s award-winning, proven solutions have been implemented successfully and rigorously tested in the most complex environments and are managing disclosures for sponsors that are responsible for over 35% of industry sponsored clinical trials posted on clincialtrials.gov. The company’s market-driven solutions and expertise enable sponsors to improve performance, mitigate compliance risk, and ultimately optimize efficiencies with clinical content lifecycle management tools, expertise and processes. TrialScope technologies are offered via a validation-ready SaaS platform hosted in a private cloud.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

Shilpa Medicare, NXI Therapeutics AG Enters Partnership

A long-term development and commercial manufacturing agreement has been...

Cantex and Headlamp Target MS Depression Using Lumos AI

Cantex Pharmaceuticals and Headlamp Health have entered a collaboration...

VoxCell and adMare Partner on Antibody Therapy Research

VoxCell BioInnovation Inc. and adMare BioInnovations have entered a...

Avenda Health Expands Unfold AI Into Midwest Cancer Care

Avenda Health said the University of Michigan Health Weiser...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »